Dr. Chris Schaber Discusses Soligenix HyBryte and Thermostabilized Vaccines
New York, New York (Newsfile Corp. - October 13, 2021) - PCG Digital In a recent interview with Kristen Kluska, a biotechnology
Ohio Northern University brings mobile clinic to Marion, sees low turnout
After delaying its first clinic earlier this month, Ohio Northern University s HealthWise Mobile Clinic made its debut in Marion Tuesday at the Marion County Fairgrounds.
Healthwise resident Makayla Wells said 15 appointments were made for the clinic, with staff bringing 20 doses of the Moderna and Johnson & Johnson vaccines. Wells said turnout for the clinic was considerably lower than previous ones. We had a better turnout prior to the pause of the Johnson & Johnson vaccine, Wells said. At some of our other clinics we were doing 400 or 500 vaccines in a day, so pretty busy clinics. But now that we ve been doing this for almost a month, a lot of people who were eager to get their vaccine, they scheduled right away.
(3)
New York, New York (Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company s plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma (CTCL).
Here are some key takeaways from the commercialization Q&A:
1. Soligenix will commercialize SGX301 in the U.S. on its own
During the presentation, the company noted that after conducting necessary due diligence and simulating different routes to commercialization, it was determined that a partnership would not be the best solution for shareholders. The licensing landscape and CTCL s small, orphan market were the key drivers behind the decision. Considering that the average biopharmaceutical licensing deal, a Phase 3 licensor will typically retain no more than 40% of the produc